Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biogennix
Irvine, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Biogennix’s bone graft products (notably Agilon and Morpheus) and systems (DirectCell) are cleared commercial devices, supported by solid clinical adoption and in vivo performance data. Their Agilon Moldable graft is indicated for use in bone voids/gaps and has demonstrated fusion rates equivalent to autograft and predicate devices in clinically relevant animal models; more than 75,000 successful human uses reported.[3][5][6]
- Therapeutic areas
- OtherRheumatology
- Modalities
- DeviceSynthetic bone graft substituteCollagen-enhanced bone graftHydroxycarbanoapatite-based graftStem cell therapy (autograft + biomaterial hybrid)
- Industry
- Implantable Medical Devices
Beyond the preview
Go deeper on Biogennix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biogennix.